# Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

> **NCT05712694** · PHASE3 · RECRUITING · sponsor: **Polaris Group** · enrollment: 300 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** ADI PEG20
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05712694
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712694, "Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05712694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*